Biomarker ID | 853 |
PMID | 22298030 |
Year | 2012 |
Biomarker | miR-30c |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Plasma |
Subjects | Humans |
Regulation | Downregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(miR-30c):- regulation of transcription by RNA polymerase II; Gene expression (Transcription); cellular protein modification process; Protein modification process; cellular metabolic process |
Experiment | prostate cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. Validation Set: 80 CaP, 44 BPH, and 54 healthy controls |
Senstivity | 79.63% |
Specificity | 68.75% |
AUC | 0.818 (95% CI: 0.749–0.887) |
Accuracy | NA |
Level Of Significance | Training: p<0.0001 |
Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | miR-30c |